Skip to main content
Top
Published in: International Journal of Clinical Oncology 4/2019

01-04-2019 | Original Article

Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population

Authors: Rong Wang, Hai-Mei Qin, Li Qin, Jing-Xi Wei, Yu-Xia Wei, Jun-Li Wang

Published in: International Journal of Clinical Oncology | Issue 4/2019

Login to get access

Abstract

Background

Emerging evidences were accumulated to support the view that GRP78 might be associated with multiple types of cancer. Given these, the aim of this study is to investigate the relationship between single nucleotide polymorphisms (SNPs) of GRP78 gene promoter and nasopharyngeal carcinoma (NPC).

Methods

Three SNPs (rs3216733, rs17840761 and rs17840762) in GRR78 promoter were estimated in 422 NPC patients and 452 controls. Genotyping was performed using SNaPshot SNP. Serum GRP78 level was performed by enzyme-linked immunosorbent assay (ELISA). Data were analyzed by SPSS 17.0 software.

Results

Significant association between rs3216733 polymorphism and NPC was observed (Cd vs. dd: OR = 0.57, 95% CI 0.43–0.76, P < 0.001; CC vs. dd: OR = 0.62, 95% CI 0.39–0.98, P = 0.043; Cd/CC vs. dd: OR = 0.58, 95% CI 0.44–0.76, P < 0.001; C vs. d OR = 0.70, 95% CI 0.57–0.86, P = 0.001). Additionally, we further found that expression were down-regulated in serum of patients with NPC carrying rs3216733 CC genotype when compared to that of dd genotype (P < 0.001).

Conclusion

The observations suggest that rs3216733 polymorphism in the GRP78 gene promoter may correlate with NPC susceptibility.
Literature
2.
go back to reference Kang M, Zhou P, Wei T, et al (2017) A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study. Am J Cancer Res 7(2):346–356PubMedPubMedCentral Kang M, Zhou P, Wei T, et al (2017) A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study. Am J Cancer Res 7(2):346–356PubMedPubMedCentral
11.
go back to reference Lei J, Zhao L, Zhang Y, et al (2018) High Glucose-induced podocyte injury involves activation of mammalian target of rapamycin (mTOR)-induced endoplasmic reticulum (ER) stress. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 45 (6):2431–2443. https://doi.org/10.1159/000488231 CrossRef Lei J, Zhao L, Zhang Y, et al (2018) High Glucose-induced podocyte injury involves activation of mammalian target of rapamycin (mTOR)-induced endoplasmic reticulum (ER) stress. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 45 (6):2431–2443. https://​doi.​org/​10.​1159/​000488231 CrossRef
26.
go back to reference Yoshida H, Haze K, Yanagi H, et al (1998) Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem 273(50):33741–33749CrossRef Yoshida H, Haze K, Yanagi H, et al (1998) Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem 273(50):33741–33749CrossRef
27.
go back to reference Li WW, Hsiung Y, Zhou Y, et al (1997) Induction of the mammalian GRP78/BiP gene by Ca2 + depletion and formation of aberrant proteins: activation of the conserved stress-inducible grp core promoter element by the human nuclear factor YY1. Mol Cell Biol 17(1):54–60CrossRefPubMedPubMedCentral Li WW, Hsiung Y, Zhou Y, et al (1997) Induction of the mammalian GRP78/BiP gene by Ca2 + depletion and formation of aberrant proteins: activation of the conserved stress-inducible grp core promoter element by the human nuclear factor YY1. Mol Cell Biol 17(1):54–60CrossRefPubMedPubMedCentral
Metadata
Title
Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population
Authors
Rong Wang
Hai-Mei Qin
Li Qin
Jing-Xi Wei
Yu-Xia Wei
Jun-Li Wang
Publication date
01-04-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 4/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1366-4

Other articles of this Issue 4/2019

International Journal of Clinical Oncology 4/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine